Diamonds and Dogs


Galmed Pharma (GLMD) gets a big upgrade. The biotech firm is up 13% thanks to an upgrade at Cantor Fitzgerald with a price target of $59 a share. Galmed is developing Aramchol, a novel, once-daily, oral therapy to treat liver diseases using fatty-acid/bile-acid conjugates (FABACs). Galmed's lead indication is non-alcoholic steatohepatitis (NASH), a major contributor to liver disease in developed countries, affecting 50 million people in the U.S. and EU5. Galmed recently announced results from a Phase 2b ARREST trial, demonstrating a strong safety profile with positive efficacy across numerous endpoints.

Investors don't like this deal. Chipmaker, Broadcom (AVGO) is down 17% after agreeing to acquire software maker, CA Technologies. The $18.9 billion all-cash acquisition has resulted in several downgrades for the semiconductor company, with Evercore noting the "loss of focus" as a big worry for investors. Broadcom sank as much as 19% its worst intraday loss since 2009.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.